Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Google Secures Pentagon AI Deal for Classified Projects 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
CANTON, Mass., April 20, 2017 -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present at the 42nd Annual Deutsche Bank Healthcare Conference in Boston. The presentation will take place at 10:40 a.m. ET on Wednesday, May 3, 2017 at the InterContinental Boston Hotel.
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its proprietary DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx technology platform is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.
About Xtampza ER
Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Contact: Alex Dasalla [email protected]
